Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + cisplatin induction chemotherapy with nimotuzumab and penpulimab followed by chemoradiotherapy in advanced head and neck cancer
ChiCTR2200064587Phase 2Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Nov 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin, nimotuzumab and penpulimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Xijing Hospital. Primary endpoint: 2-year progression-free survival. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
docetaxelcisplatinnimotuzumabpenpulimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2200064587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064587.